Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience

The alternative 2/1 schedule of sunitinib demonstrated improved toxicity compared with the traditional 4/2 schedule, with similar survival.